Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide

    Aniracetam

    Nootropics

    Status
    Approved (Italy)
    Evidence

    Small human trials, graded on 2 research benches

    Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.

    Reviewed

    01Overview

    What Aniracetam is

    The first detailed pharmacology paper, published in 1982 by the Roche group, reported that oral aniracetam prevented or reversed several forms of experimentally induced amnesia in rats and mice, with bell-shaped dose-response curves and roughly ten times the potency of piracetam (PMID: 6817363). It went on to be sold as a prescription medicine in parts of Europe under names including Ampamet and Memodrin, indicated for cognitive and behavioral symptoms in older patients, and in Japan under the names Draganon and Sarpul. It has never been approved in the United States. Nearly all of the aniracetam bought by consumers today is bulk powder or capsules supplied as a research chemical rather than a licensed medicine.

    Read the full overviewShow less

    The best characterized action is positive allosteric modulation of AMPA-type glutamate receptors. Aniracetam potentiated ionotropic quisqualate and AMPA responses in Xenopus oocytes injected with rat brain mRNA, and potentiated excitatory postsynaptic potentials in rat hippocampal slices (PMID: 1975272). Patch-clamp work in guinea pig hippocampal slices showed that it reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents (PMID: 1660156). Cocrystal structures of the GluA2 ligand-binding core later placed aniracetam at the dimer interface, where it stabilizes the closed, glutamate-bound conformation and slows deactivation (PMID: 16192394).

    Animal work consistently shows restoration of impaired performance rather than improvement of normal performance. Aniracetam improved delayed-response performance in an eight-arm radial maze in rats (PMID: 1611039), improved contextual fear conditioning in DBA/2J mice along with increased membrane-bound hippocampal gamma-PKC (PMID: 11918291), and reversed passive avoidance deficits in sleep-deprived Wistar rats (PMID: 24079994). In healthy animals the picture is different: daily oral aniracetam produced no measurable change across spatial, associative, motor and anxiety tasks in normal C57BL/6J mice (PMID: 25099639), and it had no effect on delayed matching-to-sample performance in neurologically healthy pigeons (PMID: 31002681).

    The human record is mixed and mostly from the late 1980s and early 1990s. A 109-patient, six-month, placebo-controlled multicenter study in mild to moderate probable Alzheimer type dementia reported significant differences favoring aniracetam on psychobehavioral measures (PMID: 1822317), while a 44-patient double-blind study found no difference from placebo (PMID: 3103163). A 1994 review concluded the evidence supported continued evaluation rather than established efficacy (PMID: 8199398), and a 2010 review of piracetam-like drugs reported that aniracetam and oxiracetam were no longer in clinical use (PMID: 20166767), although a 2014 analysis of 1,067 inpatient records from 20 hospitals in China listed aniracetam among the 10 most used Western drugs in patients with insomnia, at 13.4% (PMID: 25532388).

    Two practical points. First, the parent drug is short-lived: after a single 400 mg oral dose in 20 healthy men its plasma half-life was about half an hour (PMID: 19025058), and its major metabolites, anisic acid and p-methoxyhippuric acid, had half-lives 4 to 7 times longer in six elderly patients with cerebrovascular disease and low creatinine clearance than in young volunteers (PMID: 9062694); formulation chemists describe aniracetam as having low aqueous solubility and poor oral bioavailability (PMID: 30453664). Second, in February 2019 the United States Food and Drug Administration told a nootropics seller that aniracetam is not a dietary supplement ingredient and that products containing it are unapproved new drugs. In the United States it is a research-use-only compound.

    How it works

    Aniracetam is a positive allosteric modulator of AMPA-type ionotropic glutamate receptors. It binds at the two-fold axis of the GluA2 ligand-binding domain dimer interface, adjacent to the hinge of the clamshell, and stabilizes the closed glutamate-bound conformation, which slows receptor deactivation (PMID: 16192394). Functionally this reduces desensitization and prolongs the decay of fast excitatory postsynaptic currents in hippocampal slices, increasing the peak amplitude of synaptic responses (PMID: 1660156). The same potentiation was seen for ionotropic quisqualate and AMPA responses in oocytes expressing rat brain messenger RNA, with no effect on kainate, NMDA or GABA responses (PMID: 1975272). Downstream effects reported in rodents include increased prefrontal glutamate release in stroke-prone spontaneously hypertensive rats (PMID: 11852174) and contributions from the metabolites 2-pyrrolidinone and N-anisoyl-GABA (PMID: 11702095).

    Studied for

    • Cognitive enhancement
    • AMPA receptor pharmacology
    • Dementia
    • Nootropics

    Benefits listed

    • Prevented or reversed amnesia from hypercapnia, scopolamine, electroconvulsive shock and protein synthesis inhibitors in rats and mice (PMID: 6817363)
    • Improved delayed-response performance in an eight-arm radial maze in rats (PMID: 1611039)
    • Improved contextual fear conditioning and increased hippocampal gamma-PKC activation in DBA/2J mice (PMID: 11918291)
    • Reversed sleep-deprivation-induced passive avoidance deficits in Wistar rats (PMID: 24079994)
    Show 2 moreShow less
    • Reduced immobility in the forced swim test in aged rats but not young rats, an effect attributed to its metabolites (PMID: 11702095)
    • Improved psychobehavioral scores versus placebo over six months in 109 patients with mild to moderate probable Alzheimer type dementia (PMID: 1822317)

    02Research

    Free with email

    What the research shows

    Graded on 2 research benches

    Reference pages that put Aniracetam next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.

    Unlock the research summary

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • A summary of the key research
    • Safety and side effects
    • A link to the PubMed results

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    03Safety

    Aniracetam side effects and interactions

    Side effects

    Not in our record

    Our record lists no side effects for Aniracetam. That means none are recorded here, not that there are none. The Research section has the written safety notes.

    Who should not use it

    Contraindications

    No contraindication list is reproduced here from European product information. Mechanism-based and pharmacokinetic cautions: clearance depends on hepatic metabolism and renal elimination of metabolites, and elderly patients with cerebrovascular disease and low creatinine clearance showed 4 to 7 fold longer metabolite half-lives (PMID: 9062694). Positive modulation of AMPA receptors increases excitatory transmission and slows synaptic current decay (PMID: 1660156), which is a mechanism-based reason for caution in people with seizure disorders. In alcohol-preferring rats, aniracetam increased operant alcohol self-administration and potentiated cue-induced reinstatement of alcohol seeking (PMID: 23126443).

    Interactions

    Not in our record

    Our record lists no interactions for Aniracetam. That means none are recorded here, not that none exist.

    This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.

    Order Bloodwork

    04Dosing

    Free with email

    Dosing

    No dose on record

    Our record lists no dose for Aniracetam. This section holds what it does list.

    Unlock the Dosing section

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • Route

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    05Prices

    Aniracetam prices

    1 listing from 1 vendor, opening in the Featured order.

    Pack prices
    $64.99
    Lowest per mg
    Not listed
    Vendors
    1
    Listings
    1 (capsule)

    Prices as the vendors list them, last recorded 27 October 2026.

    Form
    Sort
    Aniracetam listings, in Featured order
    VendorProductPriceBuy

    Aniracetam 400 mg capsules

    capsule, capsules (400 mg)

    In stock

    $64.99

    No mg count

    Buy Aniracetam 400 mg capsules at Disguised Alpha
    Vendors selling Aniracetam(1: trust score, certificates, payment, shipping)

    Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors

    Review Aniracetam

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Aniracetam.

    06Chemistry

    Chemistry and structure

    Molecular formula
    C12H13NO3
    Molecular mass
    219.24 g/mol
    CAS number
    72432-10-1
    Half-life
    About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694).
    View on PubChem

    08Questions

    Frequently asked questions

    What is Aniracetam used for in research?

    Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057. The first detailed pharmacology paper, published in 1982 by the Roche group, reported that oral aniracetam prevented or reversed several forms of experimentally induced amnesia in rats and mice, with bell-shaped dose-response curves and roughly ten times the potency of piracetam (PMID: 6817363). It went on to be sold as a prescription medicine in parts of Europe under names including Ampamet and Memodrin, indicated for cognitive and behavioral symptoms in older patients, and in Japan under the names Draganon and Sarpul. It has never been approved in the United States. Nearly all of the aniracetam bought by consumers today is bulk powder or capsules supplied as a research chemical rather than a licensed medicine.

    The best characterized action is positive allosteric modulation of AMPA-type glutamate receptors. Aniracetam potentiated ionotropic quisqualate and AMPA responses in Xenopus oocytes injected with rat brain mRNA, and potentiated excitatory postsynaptic potentials in rat hippocampal slices (PMID: 1975272). Patch-clamp work in guinea pig hippocampal slices showed that it reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents (PMID: 1660156). Cocrystal structures of the GluA2 ligand-binding core later placed aniracetam at the dimer interface, where it stabilizes the closed, glutamate-bound conformation and slows deactivation (PMID: 16192394).

    Animal work consistently shows restoration of impaired performance rather than improvement of normal performance. Aniracetam improved delayed-response performance in an eight-arm radial maze in rats (PMID: 1611039), improved contextual fear conditioning in DBA/2J mice along with increased membrane-bound hippocampal gamma-PKC (PMID: 11918291), and reversed passive avoidance deficits in sleep-deprived Wistar rats (PMID: 24079994). In healthy animals the picture is different: daily oral aniracetam produced no measurable change across spatial, associative, motor and anxiety tasks in normal C57BL/6J mice (PMID: 25099639), and it had no effect on delayed matching-to-sample performance in neurologically healthy pigeons (PMID: 31002681).

    The human record is mixed and mostly from the late 1980s and early 1990s. A 109-patient, six-month, placebo-controlled multicenter study in mild to moderate probable Alzheimer type dementia reported significant differences favoring aniracetam on psychobehavioral measures (PMID: 1822317), while a 44-patient double-blind study found no difference from placebo (PMID: 3103163). A 1994 review concluded the evidence supported continued evaluation rather than established efficacy (PMID: 8199398), and a 2010 review of piracetam-like drugs reported that aniracetam and oxiracetam were no longer in clinical use (PMID: 20166767), although a 2014 analysis of 1,067 inpatient records from 20 hospitals in China listed aniracetam among the 10 most used Western drugs in patients with insomnia, at 13.4% (PMID: 25532388).

    Two practical points. First, the parent drug is short-lived: after a single 400 mg oral dose in 20 healthy men its plasma half-life was about half an hour (PMID: 19025058), and its major metabolites, anisic acid and p-methoxyhippuric acid, had half-lives 4 to 7 times longer in six elderly patients with cerebrovascular disease and low creatinine clearance than in young volunteers (PMID: 9062694); formulation chemists describe aniracetam as having low aqueous solubility and poor oral bioavailability (PMID: 30453664). Second, in February 2019 the United States Food and Drug Administration told a nootropics seller that aniracetam is not a dietary supplement ingredient and that products containing it are unapproved new drugs. In the United States it is a research-use-only compound.

    What forms does Aniracetam come in?

    Aniracetam is available in capsule form.

    How do I compare Aniracetam vendors?

    Compare prices, payment methods, shipping, and COA scores across 1 vendor.

    How many vendors sell Aniracetam, and what does it cost per mg?

    1 of the vendors BodyHackGuide tracks list Aniracetam (1 listing). The lowest listed price BodyHackGuide has recorded for Aniracetam is $64.99. No Aniracetam listing recorded as in stock carries a milligram count, so BodyHackGuide states no price per milligram for Aniracetam.

    Which vendors have third-party COAs for Aniracetam on file at BodyHackGuide?

    BodyHackGuide holds 1 third-party certificate record for Aniracetam, from . No editor has read any of BodyHackGuide's 1 certificate record for Aniracetam. The laboratory named on BodyHackGuide's Aniracetam certificate record is Freedom Diagnostics Testing, and the test date on it is 2 October 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.

    Related

    Articles on Aniracetam

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free